* The findings revealed that AYAs had higher initial disease severity but showed similar responses to treatment with tyrosine kinase inhibitors (TKIs) as older patients.
* Although AYAs experienced a shorter event-free survival (EFS), their overall survival (OS) rates were comparable to those of older adults, indicating the need for more research into the unique biology of CML in younger patients.